Research Analysts Issue Forecasts for Genmab A/S Q2 Earnings

Key Points

• HC Wainwright cut its Q2 2027 EPS forecast for Genmab to $0.44 from $0.59, while maintaining a Buy rating and a $70 price target.
• Genmab’s latest quarter delivered EPS of $0.56, beating the $0.36 consensus, but revenue of $1.19 billion fell just short of the $1.20 billion estimate.
• Analyst sentiment remains broadly positive: MarketBeat reports a Moderate Buy consensus and an average price target of $53.61, with nine Buy ratings among 12 analysts.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Investment analysts at HC Wainwright decreased their Q2 2027 earnings per share (EPS) estimates for Genmab A/S in a research note issued to investors on Friday, November 6th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.44 per share for the quarter, down from their previous forecast of $0.59. HC Wainwright currently has a "Buy" rating and a $70.00 price objective on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.22 per share.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.20. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.20 billion.

A number of other analysts have also weighed in on GMAB. Morgan Stanley increased their target price on Genmab A/S from $42.00 to $57.00 and gave the stock an "equal weight" rating in a research note on Friday, October 30th. Truist Financial reissued a "buy" rating and set a $67.00 target price (up from $45.00) on shares of Genmab A/S in a research note on Thursday, October 29th. TD Cowen upped their price target on shares of Genmab A/S from $43.00 to $52.00 and gave the stock a "buy" rating in a report on Monday, October 26th. Guggenheim raised their price target on shares of Genmab A/S from $58.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, October 30th. Finally, Weiss Ratings raised shares of Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a research note on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $53.61.

Genmab A/S Price Performance

GMAB opened at $53.63 on Monday. The business has a fifty day moving average of $39.18 and a 200 day moving average of $31.11. The stock has a market cap of $33.47 billion, a P/E ratio of 45.84, a PEG ratio of 2.10 and a beta of 0.73. The company has a quick ratio of 2.43, a current ratio of 2.45 and a debt-to-equity ratio of 0.74. Genmab A/S has a 52-week low of $23.62 and a 52-week high of $59.97.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of GMAB. Aberdeen Group plc purchased a new position in Genmab A/S during the 3rd quarter worth $3,948,000. ProVise Management Group LLC bought a new stake in Genmab A/S during the 3rd quarter valued at $252,000. Keybank National Association OH lifted its holdings in shares of Genmab A/S by 2.1% in the 3rd quarter. Keybank National Association OH now owns 31,730 shares of the company's stock worth $1,132,000 after buying an additional 662 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Genmab A/S by 26.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,427 shares of the company's stock worth $395,000 after buying an additional 2,380 shares during the period. Finally, Ethic Inc. lifted its holdings in shares of Genmab A/S by 64.5% in the 3rd quarter. Ethic Inc. now owns 23,015 shares of the company's stock worth $821,000 after buying an additional 9,023 shares during the period. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases.

The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Genmab operates internationally, with activities across Europe, North America and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.